C12Y 304/24046
Adamalysin
Official title: Adamalysin (3.4.24.46)
C12Y304/24046 (Adamalysin) appears on 7 US grants and 17 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 17
- Assignees
- 6
- Inventors
- 19
- Latest grant
- 1 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 2 |
| 2014 | 1 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 2 |
| 2017 | 1 | 5 |
| 2018 | 0 | 1 |
| 2019 | 1 | 0 |
| 2020 | 2 | 2 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Methods for producing antigen-binding proteins against foreign antigens1 Jul 2025US 12,342,801 B2Regeneron Pharmaceuticals, Inc.
- Transgenic mammals and methods of use thereof30 Jul 2024US 12,049,516 B2Trianni, Inc.
- Transgenic mammals and methods of use thereof6 Oct 2020US 10,793,829 B2Trianni, Inc.
- Transgenic mammals and methods of use thereof26 May 2020US 10,662,256 B2Trianni, Inc.
- Method for inhibiting ADAM proteases with cyclic peptides12 Nov 2019US 10,472,393 B2Cancer Research Technology Limited
- Methods for producing antigen-binding proteins against foreign antigens11 Sep 2025US 2025/0280805 A1Regeneron Pharmaceuticals, Inc.
- Methods for producing antigen-binding proteins against foreign antigens2 Jun 2022US 2022/0167600 A1Regeneron Pharmaceuticals, Inc.
- Humanized rodents that express heavy chain containing vl domains2 Dec 2021US 2021/0368751 A1Regeneron Pharmaceuticals, Inc.
- Transgenic mammals and methods of use thereof1 Oct 2020US 2020/0308307 A1Trianni, Inc.
- Transgenic Animals2 Jul 2020US 2020/0205384 A1Kymab Limited
Most cited
By later US patents